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SUMMARY 
Global trade and mobility of people has increased rapidly over the last 20 years. This has had 
profound consequences for the evolution and the movement of antibiotic resistance genes. 
There is increasing exposure of populations all around the world to resistant bacteria arising 
in the emerging economies. Arguably the most important development of the last two decades 
in the field of antibiotic resistance is the emergence and spread of extended-spectrum β-
lactamases (ESBLs) of the CTX-M group. A consequence of the very high rates of ESBL 
production among Enterobacteriaceae in Asian countries is that there is a substantial use of 
carbapenem antibiotics, resulting in the emergence of plasmid-mediated resistance to 
carbapenems. This article reviews the emergence and spread of multidrug-resistant Gram-
negative bacteria, focuses on three particular carbapenemases ‒ imipenem carbapenemases, 
Klebsiella pneumoniae carbapenemase, and New Delhi metallo-β-lactamase ‒ and highlights 
the importance of control of antibiotic use. 
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Introduction 
Global background 
There has been a massive increase in global trade over the last 20 years, especially 
with the rapidly emerging nations of China and India. In 2008 more than US$800 billion of 
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trade flowed between Asia and Europe and almost half the global trade in goods involved 
Europe.1 This has had profound consequences for the evolution and the movement of 
antibiotic resistance genes. Of the top ten megacities (cities with ≥10 million population) 
eight are in Asia, the other two being Mexico City and New York. These megacities place 
huge demands on public health infrastructure, particularly in relation to sewage, drinking 
water, and overcrowding. In addition, the emerging economies are often heavy users of 
antimicrobials in both medicine and agriculture, which, combined with the deficits in public 
health infrastructure, has resulted in very high rates of resistance to antibiotics, especially 
among Gram-negative bacteria. 
Global mobility has changed dramatically in the last 15 years. Travel by air has 
increased to the extent that, in 2012, >5000 billion revenue passenger-kilometres were 
recorded by the International Civil Aviation Organization.2 Passengers carry Gram-negative 
bacteria in their bowel flora, particularly Escherichia coli and Klebsiella spp. Consequently 
there is increasing exposure of populations all around the world to resistant bacteria arising in 
the emerging economies. The role of the environment in the transmission of Gram-negative 
bacteria has been reviewed in detail elsewhere.3 Unlike MRSA and enterococci, 
Enterobacteriaceae have a more fluid genome, mediated chiefly by the extensive carriage of 
conjugative plasmids that frequently carry antibiotic resistance genes as well as pathogenicity 
genes. The ability of antibiotic resistance genes to be transferred from environmental bacteria 
to medically relevant species of bacteria is well recognized.  
Emergence of extended-spectrum β-lactamases (ESBLs) 
Arguably the most important development of the last two decades in the field of 
antibiotic resistance is the emergence and spread of extended-spectrum β-lactamases (ESBLs) 
of the CTX-M group.4 Careful work by a group in Paris has shown that CTX-M resistance 
genes are present on the chromosomes of at least three species of Kluyvera, environmental 
bacteria closely associated with the rhizosphere (the complex microbial community 
surrounding plant rootlets). The resistance gene is inducible when on the chromosome but, 
once mobilized on to a plasmid with insertion sequences ISEcp1 and IS903, becomes highly 
mobile among the Enterobacteriaceae.5 CTX-M was first recognized in 1989 in an isolate 
from a cancer patient of E. coli which was resistant to third generation cephalosporins. It was 
located on an 85 kilobase conjugative plasmid and the enzyme was originally designated 
MEN-1.6 Four major groups of genetically distinct but related genotypes of CTX-M have 
emerged: 1, 2, 25, and 9.7 Of the genotypes within these groups, two have been immensely 
successful, i.e. CTX-M 15 and to a lesser extent CTX-M 14.4 CTX-M 15 is the only genotype 
present throughout India. Bearing in mind the early recognition there of the ESBL phenotype 
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and the genotyping of strains from the early 2000s, it seems most plausible that this gene 
emerged in the Indian subcontinent and has then spread throughout the world.8 CTX-M 14 
was first described in Enterobacteriaceae from Guangzhou in Southern China in 1998.9 The 
study indentifying CTX-M 14 observed a very high rate (≥35%) of ESBL production among 
E. coli in Guangzhou and, by reasoning similar to that applied to CTX-M 15 in India, it is 
most likely that CTX-M 14 emerged in China or an adjacent country during the mid-1980s, 
when locally produced cefotaxime was very widely used in hospital practice.  
Spread of ESBLs 
The movement of people around the world is a major consideration in the spread of 
multidrug-resistant (MDR) Gram-negative bacteria. Recent statistics for passenger 
movements at UK airports reveal that while the number of movements to or from the USA 
and Canada grew from 19.8 million in 2002 to 20.4 million in 2012, movements to or from 
India and Pakistan grew from 1.3 to 2.7 million over the same period, and to or from China 
and Hong Kong from 1.3 to 2.1 million. Total movements between the UK and the rest of the 
world grew from 39.5 to 50 million. Several studies have demonstrated the significance of 
this movement for antibiotic resistance. For example, Tham et al. found ESBL-producing 
bacteria in only two of 63 (3%) travellers returning to Sweden from European destinations, 
whereas they found ESBL producers in 50 of 138 (36%) of those who had travelled outside 
Europe.10 The highest colonization rate was in those returning from India (11/14, 79%) 
closely followed by Egypt (19/38, 50%) and the Middle East (4/10, 40%). The genotypes of 
CTX-M identified in the travellers matched the regional distribution described by Hawkey 
and Jones.4 All the ESBLs from travellers returning from India were CTX-M group 1 (most 
likely CTX-M 15), whereas all those returning from China were group 9 (most likely CTX-M 
14). Egypt and Thailand had a mixture of groups 1 and 9, which is consistent with studies 
from those countries. Acquisition in these countries is at least partly attributable to the 
variable quality of sewage disposal and water treatment. In India, only 47% of households 
have a latrine.11 Defecation in public places is a frequent occurrence, thus facilitating the 
spread of colonization among both local people and visitors. The situation in China is better, 
as 65% of the population have access to improved sanitation facilities (36% in India), but 
disposal of faeces can be of a variable standard especially in rural areas.12 Even in those 
countries with level 3 treatment of sewage such as the UK, sewage treatment does not fully 
remove CTX-M-producing E. coli. A recent study from the English Midlands has shown that 
significant numbers of CTX-M-producing E. coli in treated effluent are discharged into water 
courses, where they may then be acquired by people during recreational activity in what 
appears to be a perfectly clean river, and also by livestock.13 There is a paucity of data from 
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many countries in Asia on resistance rates, but the SMART study (which samples E. coli and 
Klebsiella spp. causing significant intra-abdominal infections across a range of countries 
throughout the world and subjects them to standardized antimicrobial susceptibility testing 
and characterization) shows some interesting contrasts in different Asian countries. The data 
from 2008 showed an ESBL-producing E. coli rate for China of 59.1% and for India of 
61.2%.14 This contrasts with a rate of 22% in Hong Kong and 2.9% in Malaysia, which have 
better public health infrastructures as well as reasonably controlled antimicrobial prescribing 
in both human and animal medicine. Data on ESBL carriage rates in the community are even 
scarcer. Recently all of the available studies were summarized by Woerther et al.15 Data on 
individuals with or without healthcare contact in the community are completely lacking from 
India. However, there are three studies of ESBL producers in healthy individuals in the 
community in China: Tien et al. reported a prevalence of ESBL-producing E. coli of 7% 
among 170 elderly people in Shenyang; by contrast, Li et al. reported a prevalence of 50% 
among 109 individuals in Fuzhou; and Zhong et al. found a prevalence of 51% in 567 healthy 
individuals with no healthcare contact in Hunan Province.16‒18 The high rate of carriage of 
CTX-M ESBLs in some countries is reflected in the carriage rate in those individuals in 
European countries with connections to those countries. Wickramasinghe et al. demonstrated 
this effect by showing that residents of Birmingham, UK, whose names indicated a global 
origin in either the Middle East or South Asia, had a CTX-M ESBL faecal carriage rate of 
23%, whereas those whose names indicated European origin had a carriage rate of 8%.19 
There was also a statistically significant association of carriage of CTX-M 15 among the 
Middle Eastern/South Asian individuals. A similar effect has been noted recently in Paris, 
where CTX-M-positive clinical isolates were much more prevalent in those whose birthplace 
was outside of mainland France.20 
A consequence of the very high rates of ESBL production among Enterobacteriaceae 
in Asian countries is that there is a substantial use of carbapenem antibiotics, which has 
resulted with time in the emergence of plasmid-mediated resistance to that family of drugs. Of 
the five widely encountered carbapenemase genes ‒ IMP, KPC, NDM, VIM, and OXA-48 ‒ 
this review concentrates on IMP, KPC, and NDM.  
IMP carbapenemases 
IMP carbapenemases, the first plasmid-mediated transferable carbapenemases to be 
recognized, emerged in Japan in the 1990s.21 The carbapenemases, like the CTX-M ESBL 
enzymes, have a range of genotypes that are given sequential numbers (e.g. IMP-1, IMP-2, 
etc.), with each new carbapenemase differing from previously described genotypes by at least 
one amino acid. The first genotype described, IMP-1, is the most widely encountered 
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carbapenemase in Japan. This emerged and spread rapidly among very different species of 
Enterobacteriaceae ‒ Acinetobacter and Pseudomonas spp. Nine other genotypes were 
recognized between 1995 and 2001. One of those was IMP-4, first described from a single 
isolate of Citrobacter youngae from Guangzhou in Guangdong Province of Southern China.22 
IMP-4 was encoded on a cassette in a class 1 integron on a large plasmid and was 
transferrable to E. coli. An interesting feature of both IMP and VIM metallo-β-lactamases in 
class 1 integrons is their ability to be expressed at high level in different hosts, and to be 
mobilized from one strain to another and one species to another.23 Fascinatingly, almost 
simultaneous with this first description of IMP-4 in Citrobacter youngae, there was an 
outbreak in Hong Kong of Acinetobacter baumannii carrying the IMP-4 carbapenamase.24 
There were no further reports of IMP-4 until 2005, when there was a large outbreak in 
Melbourne, Australia, predominantly in Serratia marcescens but also in Pseudomonas 
aeruginosa, which subsequently spread to seven different species of Enterobacteriaceae and 
became endemic in eastern Australia.25 Almost simultaneously Sydney experienced an 
outbreak of hospital cross-infection with Enterobacteriaceae producing IMP-4 in the same 
integron cassette array in which three other genes, qacG2, aacA4 and catB3, were also present 
within the class 1 integron.26 Interestingly the integron was found in a different genetic 
context and on a different plasmid from the original isolate from Guangzhou, suggesting 
movement either by homologous recombination or a CR1-associated mobilization. IMP-4 
continues to be a problem within Eastern Australia. Following the initial reports in 2000, it 
was not until 2009 that IMP-4 was reported again (along with IMP-8 and KPC) in China, 
where it emerged as the most prevalent carbapenemase in a nationwide surveillance study 
involving 16 teaching hospitals.27 More recent studies report the widespread occurrence of 
IMP-4 in southwest China, where a 2009‒2010 study in a 3000-bed hospital in Chongquing 
revealed 26 isolates of carbapenem-resistant Enterobacteriaceae of which 18 produced IMP-4 
and one produced KPC.28 Interestingly, 16 of the carbapenemases were in Klebsiella 
pneumoniae. A study from Fujian Medical University Union Hospital of faecal carriage 
among 303 randomly selected patients between November 2011 and January 2012 revealed a 
carriage rate of carbapenemase-producing Enterobacteriaceae of 2.6%.29 Four isolates 
produced IMP-4, four produced KPC and one of the KPC isolates also produced NDM-1. In 
Europe and North America, IMP carbapenemases are currently rare, but their widespread 
presence in both China and Australia suggests that this carbapenemase may prove to be a 
problem in the future.  
KPC carbapenemase 
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Arguably one of the most widely distributed carbapenemases in the world is K. 
pneumoniae carbapenemase (KPC). It was first described in North Carolina, USA, in 1996, 
and re-emerged in New York City in the early 2000s, causing extensive outbreaks in intensive 
care units in the Brooklyn and Bronx districts.30 KPC-1 and KPC-2 are identical: the initial 
difference was attributed to a single base pair error in sequencing and KPC-2 has been 
adopted as the correct DNA sequence. A number of other genotypes are recognized but none 
are as prevalent as KPC-2. KPC-3 has an enhanced activity against ceftazidime compared to 
cefotaxime. They are all serine-active β-lactamases which confer broad-spectrum resistance to 
all β-lactams except to high levels of temocillin. They are poorly inhibited by all the well-
known β-lactamase inhibitors, but the new β-lactamase inhibitor, avibactam, when combined 
with ceftazidime shows excellent inhibitory activity against serine-active carbapenemases 
(KPC and OXA-48) as well as ESBLs. When KPC emerged, it was confined to ST-258 
sequence type K. pneumoniae in the USA but emerged contemporaneously in Pseudomonas 
aeruginosa in Columbia and Puerto Rico. In the USA it was initially (in 2005) confined to the 
eastern seaboard with one or two states in the mid-west being affected, but the spread across 
the USA since then has been rapid. Data from the Centers for Disease Control and Prevention, 
Atlanta, on the situation in February 2014 showed that every state except Alaska and Idaho 
was affected. In many long-term care facilities, KPC is a considerable problem and is found 
in other Enterobacteriaceae. The global threat of KPC is exemplified by the experience in 
Israel. Because of a substantial problem since the late 1990s with CTX-M 2 ESBLs thought to 
have been imported by travellers from South America, carbapenems were heavily used. This 
created the ideal environment for the spread of KPC-producing K. pneumoniae that had likely 
been introduced to Israel by visitors from New York. First observed in Tel Aviv in late 2005, 
within two years it had subsequently spread to healthcare facilities throughout Israel.31  
Greece has also had a substantial problem with KPC for a number of years, and, very 
recently, Italy has moved from a situation where carbapenemase genes were carried by less 
than 5% of K. pneumoniae isolates to one where, in 2011, they were carried by 25‒50% K. 
pneumoniae isolates.32,33 This might be linked to Italy’s position as one of Europe’s heaviest 
prescribers of carbapenems and lowest users of alcohol hand-rub gel.33 In China, KPC 
appears to be frequently co-carried with IMP-4 but it is not as prevalent, and isolates solely 
producing KPC are recognized. Qi et al. at Zhejiang University first drew attention to the 
KPC problem in a study of carbapenemase genes in 95 isolates of K. pneumoniae from 13 
different hospitals across five provinces in Eastern China.34 All isolates are found to carry 
KPC-2 and many had the ST-11 sequence type (a single locus variant of ST-258), but other 
sequence types were identified and pulsed-field gel electrophoresis revealed considerable 
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diversity of the host bacteria, suggesting extensive transmission via plasmids into different 
backgrounds. More recently, KPC has also been recognized in E. coli and in other locations 
within China.35 
NDM carbapenemase 
In 2008, a new metallo-carbapenamase only distantly related to the IMP and VIM 
genes was identified in a Swedish patient of Indian origin who had returned to India for 
medical treatment and then been admitted to hospital in Sweden.36 Metallo-carbapenemase-
producing K. pneumoniae was isolated from his urine, and E. coli carrying the same metallo-
β-lactamase gene was isolated from his faeces. The carbapenemase, New Delhi metallo-β-
lactamase (NDM), was named after the location of his recent hospital care in India. Later 
sporadic findings of this new NDM gene in the UK could in at least 50% of cases be linked to 
receiving hospital care in India, Bangladesh, or Pakistan.37 India is a frequent destination for 
medical tourism from the UK.38 Data on the distribution of NDM in South Asia are scarce, 
but NDM is probably one of the most widely distributed carbapenemases in South Asia, along 
with OXA-48, which can be difficult to detect phenotypically. NDM has also spread to many 
other parts of the world, generally, as in the UK, as sporadic importations. Carbapenem-
resistant Klebsiella spp. and to a lesser extent E. coli are increasingly documented in hospital 
facilities in India: for example, Saleem et al. have described increasing carbapenem resistance 
in K. pneumoniae causing late-onset sepsis in a neonatal intensive care unit in Karachi. 
Whereas, before 2010, isolates of K. pneumoniae from babies with late-onset sepsis were only 
sporadically resistant to imipenem, in 2010, 23% (6/26) of the isolates were imipenem 
resistant and, by 2011, 72% (13/18) were imipenem resistant.39  
Carbapenemase-producing Enterobacteriaceae in the UK 
In the UK, all five major groups of carbapenemases, as well as rarer enzymes, have 
been reported by the reference laboratory. The UK picture is dominated by KPC, but most 
KPC-producing isolates were either from screening samples or from clinical specimens in 
northwest England. The next most frequently seen carbapenemase is NDM, which is 
distributed across the UK but with higher numbers in the London region. OXA-48 is also 
frequently encountered and many of these are attributable to episodes of cross-infection, 
particularly in intensive care units. I believe that the UK will see an increasing pressure in the 
future from imported NDM, which may, if not dealt with vigorously, cause local problems. 
The currently endemic KPC in northwest England is being controlled and may yet be 
eradicated, but we will experience further pressure from imported cases. In my view, the UK 
should be especially alert to future importations of NDM-1 and IMP-4 from Asia. Moreover, 
OXA-48 may well become locally endemic, as its detection is extremely problematic.  
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The environment and Gram-negative resistance 
Faecal carriage by humans is a major source of MDR Gram-negative bacilli within the 
hospital environment and can be selected by antimicrobial therapy. Once MDR Gram-
negative resistance genes become widespread in the community, the opportunity exists for 
bacteria to be more widely disseminated through the environment and establish a cyclical 
pattern of distribution.3 River sediment has recently been shown to be a substantial reservoir 
of antibiotic resistance genes.40 Using a metagenomic approach, the authors demonstrated that 
these were present both in culturable and unculturable bacteria. Even the use of level 3 
sewage treatment in the UK does not prevent significant numbers of CTX-M-producing 
Enterobacteriaceae being released into the aquatic environment.13 They can then be acquired 
by people engaged in water sports, as well by farm animals, which may explain the 
acquisition by dairy herds of CTX-M 14 and 15, the two most prevalent types in humans.41 
Once in the human food chain, the cycle can be completed (Figure 1). World production of 
poultry and pig meat has been increasing rapidly. Statistics from the UN’s Food and 
Agriculture Organization in 2011 show that China produced 17.6 million tons of poultry meat 
and Europe produced 16.4 million tons.42 Production of pig meat was 62.0 million tons in 
China, 26.8 million tons in Europe and 12.1 million tons in North and South America. 
Chinese production of pig meat represents 5% of total world production. The use of 
antibiotics in animal husbandry in China and many other Asian countries is substantial, 
although detailed data are not generally available. Xinhua news agency has published a report 
from the Ministry of Health and National Antibacterial Resistance Investigation Net on the 
production of antibiotics in China in 2007.43 In all, 210,000 tons of antibiotics were produced 
that year, of which 30,000 tons were exported and 46% was used in food animals. The total 
agricultural and medical consumption of antibiotics thus amount to 136 grams per person per 
year. By contrast, antibiotic consumption England in 2013 was 18 grams per person per year. 
Several factors driving antimicrobial use in medicine in both China and India need to be 
addressed urgently to reduce the overall selection pressure.  
Aquaculture, including fish farming, is another aspect of environmental and 
agricultural usage of antibiotics that gives cause for concern. In Scandinavian countries, the 
use of antibiotics in aquaculture has been greatly reduced by the development of vaccines and 
alternative farming methods, but this is not true in warm water aquaculture where 
antimicrobials, especially quinolones, are extensively used. Chinese aquacultural production 
has risen from six million tons in 1990 to 32 million tons in 2008, when it represented 62% of 
world production.42 The first study of antibiotic-resistant bacteria in farmed fish in China was 
published by Jaing et al. in 2012.44 They studied farmed fish from 15 market outlets across 
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Guangdong province (the Chinese province with the greatest production of farmed fish) and 
looked for ESBLs and plasmid-mediated quinolone resistance genes. Escherichia coli 
colonies were taken from non-selective media (one colony per sample) from the gut contents 
of each of 20 fish from 15 different markets. Eighty were ciprofloxacin resistant, of which 30 
out of 80 carried qnrB genes and 16 out of 30 isolates carried qnrS. Other significant 
quinolone resistance-determining genes [qnrD and aac(6′)-Ib-cr] were also found in the 
isolates, as well as a small number of ESBL genes (blaCTX-M-14 and blaCTX-M-79), the most 
frequently occurring genotypes in the Chinese population.44  
Future control of MDR Gram-negative bacilli around the world 
Effective control requires good surveillance, and it is somewhat disquieting that, in the 
2014 antimicrobial resistance report on surveillance from the World Health Organization, 
only 50% of member states returned data sets on nine key ‘drug‒bug’ combinations.45 Returns 
were highest in European states (38/53, 72%), but low in the Southeast Asian states (6/11, 
55%). No data were available for the 2013 data collection exercise from either India or 
Indonesia, countries of populations of 1.2 billion and 400 million, respectively. Data are also 
lacking from many African countries. If we are to combat the rise and global spread of MDR 
Gram-negative bacilli, all countries must contribute to accurate and timely surveillance. 
Surveillance is information for action: the only country yet to have successfully controlled 
carbapenemase-producing Enterobacteriaceae is Israel, which launched a concerted 
programme of screening and cohort isolation.46 This level of intervention will be difficult to 
introduce in many parts of the world where there are weak laboratory facilities, poor infection 
control, and widespread prescribing of antibiotics. The threat for the future appears to come 
largely from the Asian region, where increasing wealth and intensification of both medical 
practice and farming results in increased usage of antibiotics. China’s introduction of controls 
of antibiotic consumption is extremely welcome. Activity in India appears modest thus far. As 
African nations become wealthier and more agriculturally intensive, we may expect the same 
pattern to be repeated. If we are to avoid squandering the valuable resource of antimicrobials, 
we must act globally. 
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Figure 1. Principal transfer pathways for antibiotic resistance genes in humans, animals, food, 
and the environment. (Reproduced with permission from The Joint Working Group of Defra’s 
Antimicrobial Resistance Co-ordination (DARC) and Advisory Committee on Antimicrobial 
Resistance and Healthcare Associated Infections (ARHAI). ESBLs ‒ a threat to human and 
animal health? 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215180/dh_13
2534.pdf [accessed 16.01.15]). 
 
 
